US 11,702,424 B2
Bicyclic-fused heteroaryl or aryl compounds
John David Trzupek, Arlington, MA (US); Katherine Lin Lee, West Newton, MA (US); Mark Edward Bunnage, Concord, MA (US); Seungil Han, Mystic, CT (US); David Hepworth, Concord, MA (US); Frank Eldridge Lovering, Acton, MA (US); John Paul Mathias, Concord, MA (US); Nikolaos Papaioannou, Newton, MA (US); Betsy Susan Pierce, East Lyme, CT (US); Joseph Walter Strohbach, Wentzville, MO (US); Stephen Wayne Wright, Old Lyme, CT (US); Christoph Wolfgang Zapf, Marlborough, MA (US); Lori Krim Gavrin, Villanova, PA (US); Arthur Lee, San Carlos, CA (US); David Randolph Anderson, Salem, CT (US); Kevin Joseph Curran, Somerset, NJ (US); Christoph Martin Dehnhardt, Burnaby (CA); Eddine Saiah, Brookline, MA (US); Joel Adam Goldberg, New Orleans, LA (US); Xiaolun Wang, San Diego, CA (US); Horng-Chih Huang, Chesterfield, MO (US); Richard Vargas, Bedford, MA (US); Michael Dennis Lowe, White Plains, NY (US); and Akshay Patny, Waltham, MA (US)
Assigned to Pfizer Inc., New York, NY (US)
Filed by Pfizer Inc., New York, NY (US)
Filed on Aug. 18, 2020, as Appl. No. 16/996,117.
Application 16/996,117 is a continuation of application No. 16/411,679, filed on May 14, 2019, granted, now 10,793,579.
Application 16/411,679 is a continuation of application No. 15/862,691, filed on Jan. 5, 2018, granted, now 10,329,302, issued on Jun. 25, 2019.
Application 15/862,691 is a continuation of application No. 15/232,892, filed on Aug. 10, 2016, granted, now 9,879,022, issued on Jan. 30, 2018.
Application 15/232,892 is a continuation of application No. 14/678,114, filed on Apr. 3, 2015, granted, now 9,458,168, issued on Oct. 4, 2016.
Claims priority of provisional application 61/975,473, filed on Apr. 4, 2014.
Prior Publication US 2020/0377511 A1, Dec. 3, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 491/056 (2006.01); C07F 7/18 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 217/02 (2006.01); C07D 217/22 (2006.01); C07D 217/24 (2006.01); C07D 239/86 (2006.01); C07D 239/88 (2006.01); C07D 263/24 (2006.01); C07D 207/273 (2006.01); C07D 498/04 (2006.01); C07D 209/52 (2006.01); A61K 31/4015 (2006.01); A61K 31/47 (2006.01); A61K 31/4709 (2006.01); A61K 31/4725 (2006.01); A61K 31/517 (2006.01); A61K 31/5377 (2006.01); C07C 69/94 (2006.01); A61K 31/541 (2006.01); A61K 45/06 (2006.01); C07D 207/26 (2006.01); C07D 215/48 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01); C07D 405/12 (2006.01); C07D 407/14 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01); C07D 487/04 (2006.01); A61K 31/40 (2006.01); C07D 207/08 (2006.01); C07D 207/267 (2006.01)
CPC C07D 491/056 (2013.01) [A61K 31/40 (2013.01); A61K 31/4015 (2013.01); A61K 31/47 (2013.01); A61K 31/4709 (2013.01); A61K 31/4725 (2013.01); A61K 31/517 (2013.01); A61K 31/5377 (2013.01); A61K 31/541 (2013.01); A61K 45/06 (2013.01); C07C 69/94 (2013.01); C07D 207/08 (2013.01); C07D 207/26 (2013.01); C07D 207/267 (2013.01); C07D 207/273 (2013.01); C07D 209/52 (2013.01); C07D 215/48 (2013.01); C07D 217/02 (2013.01); C07D 217/22 (2013.01); C07D 217/24 (2013.01); C07D 239/86 (2013.01); C07D 239/88 (2013.01); C07D 263/24 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 407/14 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01); C07D 487/04 (2013.01); C07D 498/04 (2013.01); C07F 7/1804 (2013.01)] 8 Claims
 
1. A pharmaceutical combination comprising 1-(((2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide, or a pharmaceutically acceptable salt thereof, and a JAK1 inhibitor, or a pharmaceutically acceptable salt thereof.